OBJECTIVE

2

To observe the clinical efficacy and safety of Fuzheng yangxue ointment in the intervention of chemotherapy-induced myelosuppression.

METHODS

2

The data of 200 patients were collected retrospectively， who were diagnosed as malignant tumors in our hospital for the first time from January 2018 to December 2020 and were to receive the chemotherapy scheme of “paclitaxel combined with platinum”. According to whether Fuzheng yangxue ointment was used or not， they were divided into trial group and control group， with 100 cases in each group. The control group received routine chemotherapy， and the trial group took Fuzheng yangxue ointment orally after the first chemotherapy until the end of this chemotherapy cycle. The time of the first occurrence of myelosuppression， the incidence of myelosuppression， the use of rescue drugs， quality of life and other indicators were compared between 2 groups.

RESULTS

2

After the first chemotherapy， white blood cell count， neutrophil count， the levels of platelet and hemoglobin in control group were significantly lower than those before the first chemotherapy （

P

＜0.05）. The white blood cell count and neutrophil count of patients in the trial group were significantly lower than those before the first chemotherapy （

P

＜0.05）， but significantly higher than those in the control group （

P

＜0.05）. The incidence of myelosuppression in the trial group （39.00%） was significantly lower than that （63.00%） in control group （

P

＜0.05）. The occurrence time of myelosuppression for the first time in the trial group （11.0th day after chemotherapy） was later than that in the control group （6.7th day after chemotherapy）. During the first chemotherapy cycle， the number of patients in the control group （28 cases） using drugs for increasing white cells was significantly higher than that in the trial group （11 cases） （

P

＜0.05）. After the first chemotherapy， KPS scores of patients in both groups were significantly lower than those before the first chemotherapy （

P

＜0.05）， but KPS scores of patients in the trial group were significantly higher than those in the control group （

P

＜0.05）. After the first chemotherapy， the scores of fatigue， anorexia， dizziness， palpitation， nausea and vomiting， and spontaneous sweating and night sweating in 2 groups were significantly higher than those before the first chemotherapy， but the scores of spontaneous sweating and night sweating in the trial group were significantly lower than those in the control group （

P

＜0.05）. The levels of glutamic pyruvic transaminase， glutamic oxaloacetic transaminase， urea and creatinine in the two groups were within the normal range before and after the first chemotherapy.

CONCLUSIONS

2

Fuzheng yangxue ointment can effectively reduce the incidence of chemotherapy-induced myelosuppression， delay the time of myelosuppression， reduce the consumption sum of clinical remedial drug for increasing white cells/ for increasing platelet， reduce the score of TCM syndrome and improve the quality of life of patients.